Xiaoyan Li, Jinying Chen, Mei Kong, Xu Su, Ming Zou, Liru Guo
Clin Lab. 2014;60(3):347-61. doi: 10.7754/clin.lab.2013.130334.
Diagnosis of viral respiratory tract infections clinically is often nonspecific, and a rapid, high-throughput laboratory technique which can detect major respiratory viruses is desirable.
Two liquid chip panels were developed which used a target-enriched multiplexed RT-PCR amplification followed by Luminex liquid chip hybridization based on xMAP technology. One was for the detection of 5 type/ subtypes of the influenza virus (called Influenza Panel), the other was for the identification of 14 major respiratory viruses, including emerging human metapneumovirus (HMPV), coronavirus (CoV NL63, HKU1), human bocavirus (HBoV), and WU polyomavirus (WUPyV) (called Respiratory Panel). The analytical sensitivity and specificity of these two panels were determined. 108 throat swabs from influenza-like-illness (ILI) cases and 88 nasopharyngeal aspirates (NPA) from hospitalized children with lower respiratory tract infections (LRTI) were used to evaluate the two panels.
The Influenza Panel returned the analytical sensitivity of 4 - 10 copies vRNA/microL of sample for seasonal H1N1, H3N2, pandemic H1N1, and B, and 200 copies vRNA/microL of sample for H5. The analytical sensitivity of the Respiratory Panel was as follows: 10 - 150 copies vRNA/microL of sample for most of the viral targets tested in this panel except RSV (400 copies vRNA/microL of sample). No cross reactivity was observed for both panels. As determined by commercial multi-PCR kit and conventional PCR (for HBoV and WUPyV), the diagnostic sensitivity of the Respiratory Panel for each viral targets ranged from 50.0% to 100.0%, the diagnostic specificity was 96.2%-100.0%, and accordance rate was 93.2% - 100.0%, the kappa correlation of eight viral targets was > 0.75.
Two liquid chip assay panels, developed based on xMAP technology, can detect 5 types/subtypes of influenza viruses and 14 respiratory viruses simultaneously in one reaction in 6 hours. They are potentially rapid, sensitive, specific, and high throughput diagnostic tools for major viral pathogens associated with respiratory tract infection.
临床上病毒性呼吸道感染的诊断往往缺乏特异性,因此需要一种能够快速、高通量检测主要呼吸道病毒的实验室技术。
开发了两种液相芯片检测板,采用基于xMAP技术的靶标富集多重逆转录聚合酶链反应(RT-PCR)扩增,随后进行Luminex液相芯片杂交。一种用于检测5种流感病毒型/亚型(称为流感检测板),另一种用于鉴定14种主要呼吸道病毒,包括新出现的人偏肺病毒(HMPV)、冠状病毒(CoV NL63、HKU1)、人博卡病毒(HBoV)和WU多瘤病毒(WUPyV)(称为呼吸道检测板)。测定了这两种检测板的分析灵敏度和特异性。使用108份流感样疾病(ILI)病例的咽拭子和88份住院下呼吸道感染(LRTI)儿童的鼻咽抽吸物(NPA)来评估这两种检测板。
流感检测板对季节性H1N1、H3N2、大流行H1N1和B型流感病毒的分析灵敏度为每微升样品4 - 10个病毒RNA(vRNA)拷贝,对H5型流感病毒为每微升样品200个vRNA拷贝。呼吸道检测板的分析灵敏度如下:除呼吸道合胞病毒(RSV,每微升样品400个vRNA拷贝)外,该检测板中大多数病毒靶标的灵敏度为每微升样品10 - 150个vRNA拷贝。两种检测板均未观察到交叉反应。通过商业多重PCR试剂盒和常规PCR(用于HBoV和WUPyV)测定,呼吸道检测板对每种病毒靶标的诊断灵敏度为50.0%至100.0%,诊断特异性为96.2% - 100.0%,符合率为93.2% - 100.0%,8种病毒靶标的kappa相关性>0.75。
基于xMAP技术开发的两种液相芯片检测板能够在6小时内一次反应同时检测5种流感病毒型/亚型和14种呼吸道病毒。它们可能是用于检测与呼吸道感染相关的主要病毒病原体的快速、灵敏、特异且高通量的诊断工具。